SON-1010: an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy
Published in Frontiers in Immunology
SB221: A proof-of-concept study to assess the combination of SON-1010 (IL12-FHAB) and atezolizumab in patients with platinum-resistant ovarian cancer: Trial in Progress
Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Low Dose Interleukin-6 (SON-080) for Neuropathies: Toxicology and Clinical Plans
Presented at the 2024 American Association of Cancer Research (AACR) Annual Meeting
Interim Analysis of a Phase 1 Study Using IL12-FHAB with Optimized Pharmacokinetics
Presented at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
Clinical Development of a Novel Form of Interleukin-12 with Extended Pharmacokinetics
Presented at the 2023 American Association of Cancer Research (AACR) Annual Meeting
An Innovative Human Platform for Targeted Delivery of Bispecific Interleukins to Tumors
Presented at the 2022 American Association of Cancer Research (AACR) Annual Meeting
Toxicity Profile of Interleukin 12 Attached to a Fully Human Albumin Binding Domain (FHAB™) in Cynomolgus Macaques
Presented at the 2021 American Association of Cancer Research (AACR) Annual Meeting
A Novel Strategy to Produce High Level and High Purity of Bioactive IL15 Fusion Proteins from Mammalian Cells
Protein Expression and Purification 148 (2018) 30–39
In vivo Effect of Albumin Binding Domains (ABD) Attached to Immune Modulators
Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting
